跳到主要內容區塊

講座教師

王憶卿
Wang, Yi-Ching, Ph.D.
職稱
講座教授(Chair professor)
電話
(06) 235-3535 ext 5502
傳真
(06) 274-9296
Email
ycw5798@mail.ncku.edu.tw
學經歷
學歷:1993 密西根州立大學遺傳學 博士

經歷:1995 中山醫學大學分子毒理所 副教授

        1999 臺灣師範大學生命科學系 教授

        2006 成功大學醫學院藥理所 特聘教授

        2015 成功大學醫學院藥理所 講座教授
學科專長
分子癌生物學,致癌蛋白轉錄調控,抑癌蛋白曩泡運輸,抗癌藥物研發。
研究興趣
 

王憶卿教授針對各種抑癌基因、致癌基因探討其變異性與肺癌形成的相關性;這些變異性研究包括基因突變、基因多形性、基因缺失、促進子過度甲基化、mRNA與蛋白質表達失常等分析。除了傳統的single-gene approach,王教授亦以genome-wide approach,針對癌細胞之基因體套數異常、基因體表現圖譜、基因體甲基化圖譜進行分析,希望能鑑定出更多許肺癌形成、早期偵測、預後監測的novel genes(新穎基因),目前研究ZFN322A致癌蛋白轉錄調控、Rab37囊泡運輸蛋白癌轉移抑癌機制,並建立細胞模式及動物模式研究抗癌藥物。王教授二十年來於國際學術期刊發表了百篇研究論文,並獲三次科技部傑出獎。希望在科學研究的過程中學習,並對台灣地區肺癌的成因、預防、預後有所貢獻。

實驗室人員
博士後研究員:謝智雄博士,郭懿瑩 博士  
博士班學生:
碩士班學生:蔡宇柔,黃士宣,楊侑恩,謝宏嘉,楊佩姍,胡孟璇
研究助理:張欣慈
 

博士班畢業生:
曾若嘉 博士(慈濟大學人類遺傳所副教授)
許瀚水 博士(陽明大學急症所教授)
邱建智 博士(高雄醫大學生技系教授)
林若凱 博士(台北醫學大學生藥所副教授)
李慶孝 博士(仁德醫專醫事檢驗科主任)
張哲維 博士(生技公司研發經理)
吳秋逸 博士(美國哈佛大學博士後研究員)
譚一泓 博士(美國芝加哥大學博士後研究員)
羅芳宜 博士(長庚大學醫科博士後研究員)
黃信銘 博士(台大醫技所博士後研究員)
陳家揚 博士(中研院所博士後研究員)

湯硯安   博士(生技公司研發經理)
蔡宗翰 博士(科學中藥研發員)
郭懿瑩 博士(成大藥理所博士後研究員)
任婕羽 博士(New York University博士後研究員)

廖昇佑 博士(University of Washington博士後研究員) 

  碩士班畢業生:
蔡侑庭(美國Ohio State Univ. 博士班)
許貝君(藥廠臨床試驗分析專員)
魏子堂(Stanford Cardiovascular Institute博士後研究員)
毛久珊(嬌生製藥公司專員)
楊宗瀚(後醫系學生)
楊奕婕(台大癌生所博士班)
吳靜琪(成大醫院藥師)
陳湘婷(高雄醫學大學附設醫院藥師)
蒲詩雯(成大醫醫院研究助理)
陳美瑜(藥師)
陳政宏(藥師)
陳其欣(台大公衛所博士班)
黃鈺琳(藥師)
施詠馨(藥師)
李宗信(生技公司研發專員)
胡富涵(陽明大學助教)
呂英鴻(製藥公司研發專員)
林建瑜(生技公司研發專員)
陳奕潔(製藥公司研發專員)
蘇靖欽(藥師)
卓書慧 (藥師)
吳莉婷(生技公司研發專員)
陳玉婷(生技公司研發專員)
林哲仲 (服役)
代表性著作
 .
J . Jen, Y.-T. Chen, L.-T. Wu, C.-Y. Liu, Y.-C. Shieh, W.-W. Lai, Yi-Ching Wang*. 2018. Oncogenic zinc finger protein ZNF322A promotes stem cell-like properties in lung cancer through transcriptional suppression of c-Myc expression. Cell Death and Differentiation. DOI: 10.1038/s41418-018-0204-6
 .
H.-T. Tzeng, C.-C. Su, C.-P. Chang, W.-W. Lai, W.-C. Su, Yi-Ching Wang*. 2018. Rab37 in lung cancer mediates exocytosis of soluble ST2 and thus skews macrophages towards tumor-suppressing phenotype. Int. J. Cancer. 143, 1753–1763. (cover article of Oct 1 2018 issue)
 .
S.-H. Cho, I.-Y. Kuo, P.-J. Lu, H.-T. Tzeng, W.-W. Lai, W.-C. Su, Yi-Ching Wang*. 2018. Rab37 mediates exocytosis of secreted frizzled-related protein 1 to inhibit Wnt signaling and thus suppress lung cancer stemness. Cell Death and Disease. 29;9(9):868.
 .
J. Jen, Y.-A. Tang, Y.-H. Lu, C.-C. Lin, H.-S. Hsu, W.-W. Lai, Yi-Ching Wang*. 2017. Oct4 transcriptionally regulates the expression of long non-coding RNAs NEAT1 and MALAT1 to promote lung cancer progression. Mol Cancer 16(1):104.
 .
S.-Y. Liao, C.-W. Chiang, C.-H. Hsu, Y.-T. Chen, J. Jen, H.-F. Juan, W.-W. Lai, and Yi-Ching Wang*. 2017. CK1δ/GSK3b/FBXW7a axis promotes degradation of the ZNF322A oncoprotein to suppress lung cancer progression. Oncogene 36(41):5722-5733.
 .
J.-M., Shieh, Y.-A. Tang, F.-H. Hu, W.-J. Huang, Y.-J. Wang, T.-W. Wang P. Lin, Yi-Ching Wang*. 2017. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against non-small cell lung cancer. Int. J. Cancer 140(10):2375-2386.
.
H.-T. Tzeng, C.-H. Tsai, Y.-T. Yen, H.-C. Cheng, Y.-C. Chen, S.-W. Pu, Y.-S. Wang, Y.-S. Shan, Y.-L. Tseng, W.-C. Su, W.-W. Lai, L.-W. Wu*, Yi-Ching Wang*. 2017. Dysregulation of Rab37-mediated cross-talk between cancer cells and endothelial cells via thrombospondin-1 promotes tumor neovasculature and metastasis. Clin. Cancer Res. 23(9):2335-2345. (highlighs of May 2017 issue)
. Jayu Jen, Yi-Ching Wang*. 2016. Zinc finger proteins in cancer progression. J. Biomed. Sci. 23(1):53 (invited review)
. H.-T. Tzeng, Yi-Ching Wang*. 2016. Rab-mediated vesicle trafficking in cancer. J. Biomed. Sci. 23(1):70 (invited review)
. J. Jen, L.-L. Lin, H.-T. Chen, S.-Y. Liao, F.-Y. Lo, Y.-A. Tang, W.-C. Su, R. Salgia, C.-L. Hsu, H.-C. Huang, H.-F. Juan*, Yi-Ching Wang*. 2016. Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer. Oncogene 5;35(18):2357-69.  
. Y.-A. Tang, C.-H. Chen, H. S. Sun, C.-P. Cheng, V. S. Tseng, H.-S. Hsu, W.-C. Su, W.-W. Lai, Yi-Ching Wang*. 2015. Global Oct4 target gene analysis reveals novel downstream PTEN and TNC genes required for drug-resistance and metastasis in lung cancer. Nucleic Acids Res. 43(3):1593-608
. R.-C. Tseng, J.-M. Chang, J.-H. Chen, W.-R. Huang, Y.-A. Tang, I.-Y. Kuo, J.-J. Yan, W.-W. Lai, Yi-Ching Wang*. 2015. Deregulation of SLIT2-mediated Cdc42 activity is associated with esophageal squamous carcinoma cancer metastasis and poor prognosis. J. Thorac. Oncol. 10(1):189-198
Tsai CH, Cheng HC, Wang YS, Lin P, Jen J, Kuo IY, Chang YH, Liao PC, Chen RH, Yuan WC, Hsu HS, Yang MH, Hsu MT, Wu CY, Wang YC*2014. Small GTPase Rab37 targets tissue inhibitor of metalloproteinase 1 for exocytosis and thus suppresses tumor metastasis. Nat Commun 2014 Sep 3;5:4804
. Tseng RC, Chang JM, Chen JH, Huang WR, Tang YA, Kuo IY, Yan JJ, Lai WW*, Wang YC*. 2014. Deregulation of SLIT2-mediated Cdc42 activity is associated with esophageal squamous carcinoma cancer metastasis and poor prognosis. J. Thorac. Oncol. doi: 10.1097/JTO.00369
Lin RK, Wang YC*2014. Dysregulated transcriptional and post-translational control of DNA methyltrasferases in cancer. Cell Biosci 2014 4: 46 (invited review)

 Cheng CP, Kuo IY, Alakus H, Frazer KA, Harismendy O, Wang YC*, Tseng VS*. 2014. Network-based analysis identifies epigenetic biomarkers of esophageal squamous cell carcinoma progression. Bioinformatics 2014 Jul 10. pii: btu433.

. Yang YC, Tang YA, Shieh JM, Lin RK, Hsu HS, Wang YC*. 2014. DNMT3B overexpression by deregulation of FOXO3a-mediated transcription repression and MDM2 overexpression in lung cancer. J. Thorac. Oncol. 9(9):1305-15.
Tseng RC, Huang WR, Lin SF, Wu PC, Hsu HS, Wang YC*. 2014. HBP1 promoter methylation augments the oncogenic β-catenin to correlate with prognosis in NSCLC. J. Cell Mol. Med. 18(9):1752-61.

Huang WJ, Tang YA, Chen MY, Wang YJ, Hu FH, Wang TW, Chao SW, Chiu HW, Yeh YL, Chang HY, Juan HF, Lin P, Wang YC*. 2014. A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies. Cancer Lett 28;346:84-93 (featured article).

Kuo IY, Wu CC, Chang JM, Huang YL, Lin CH, Yan JJ, Sheu BS, Lu PJ, Chang WL, Lai WW*, Wang YC*. 2014. Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression. Int J Cancer 135: 563-573 (cover article).
Chang HY, Huang HC, Huang TC, Yang PC*, Wang YC*, Juan HF*. 2012. Ectopic ATP synthase blockade suppresses lung adenocarcinoma growth by activating the unfolded protein response. Cancer Res, 72:4696-4706.
. Tang YA, Lin RK, Tsai YT, Hsu HS, Yang YC, Chen CY, Wang YC*. 2012. MDM2 overexpression deregulates the transcriptional control of RB/E2F leading to DNA methyltransferase 3A overexpression in lung cancer. Clin. Cancer Res. 18:4325-4333.
. Lo FY, Tan YH, Cheng HC, Salgia R, Wang YC*. 2011. An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer. Cancer 117:5344-50 (highlighted article).
Chen JY, Tang YA, Huang SM, Juan HF, Wu LW, Sun YC, Wang SC, Wu KW, Balraj G, Chang TT, Li WS*, Cheng HC*, Wang YC*2011. A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer Angiogenesis and Metastasis Pathways. Cancer Res. 71:473-483.
. Lin RK, Wu CY, Chang JW, Juan LJ, Hsu HS, Chen CY, Lu YY, Tang YA, Yang YC, Yang PC, Wang YC*. 2010. Dysregulation of p53/Sp1 control leads to DNA methyltransferase 1 overexpression in lung cancer. Cancer Res. 70:5807-5817.
. Lin RK, Hsieh YS, Lin P, Hsu HS, Chen CY, Tang YA, Lee CF, Wang YC*2010. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J. Clin. Invest., 120:521–532 (cover article).
Tseng RC, Lee SH, Hsu HS, Chen BH, Tsai WC, Tzao C*, Wang YC*2010. SLIT2 attenuation during lung cancer progression deregulates beta-catenin and E-cadherin and associates with poor prognosis. Cancer Res., 70: 543-551.
 
獎助
.

第27屆王民寧獎 [醫藥科技傑出貢獻獎] 2017

.

科技部特約研究 2017-2020

三次科技部/ 國科會傑出獎 2004-2007, 2010-2013,2014-2017 [E xcellent Research award of National Science Council, Taiwan. (2004-2007 , 2010-2013,2014-2017 )]

成功大學講座教授 2014-2017 [Chair professor of National Cheng Kung University (2014-2017)]

成功大學特聘教授 1997-2013 [D istinguished professor of National Cheng Kung University (1997-2013)]

董大成癌症基礎研究傑出獎 2013

成大醫學院最佳論文獎 2010 [Outstanding publication award of National Cheng Kung University 2010]

成杏基金會優秀論文獎 2008-2017[Excellent paper award of Cheng Hsin Medical Society 2008-2017]

藥理學會傑出研究獎 [Excellent Research award in Pharmacology Society, Taiwan. (2008)]
文化大學傑出校友 [Distinguished alumnus of Chinese Culture University, (2007)]
目前之研究計畫
計畫名稱
補助或委託機構 起訖年月 擔任工作

Investigation of Oct4-centered transcriptional networks in lung cancer progression and drug resistance

Oct4轉錄調控網路參與肺癌惡化及抗藥性之機制探討

科技部 個人型計畫

MOST RO1 Project
2013/8/1 ~ 2016/7/31

主持人

PI

The vesicle trafficking and anti-tumorigenicrole of Rab37 small GTPase using lung cancer as a model

以肺癌為模式探討Rab37 在囊泡運輸及抑癌機制中之角色-Rab37 蛋白磷酸化及其效應蛋白在囊泡運輸及抑癌機制之角色

科技部 整合型研究計畫

2015/8/1~

2018/7/31

主持人

PI

Coordinate regulation of immune evasion in lung tumor microenvironment by Rab37 in infiltrating immune cells and WDR4 in tumor cells

浸潤免疫細胞之Rab37與癌細胞之WDR4協同調控肺腫瘤微環境中逃避免疫攻擊的機制

科技部 創新轉譯研究計畫

2017/8/1~

2020/7/31

主持人

PI

 

Targeting metabolic switch of lung cancer stem cells driven by ZNF322A transcription factor

以ZNF322A轉錄因子所導致之肺癌幹細胞代謝為治療標靶研究

國衛院 創新研究計畫

2018/1/1~

2020/7/31

主持人

PI

 

701 台南市大學路1號
電話:06-2353535#5471  傳真:06-2749296
Email:em75470@email.ncku.edu.tw
© 2017 All Rights Reserved Terms of Use and Privacy Policy